Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin 287 vs once-daily insulin glargine in insulin-naïve type 2 diabetes
2018-000322-63Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of human insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Aug 2018; status: completed.
02
Drugs
human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-000322-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000322-63.